Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers
Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved by the FDA in 2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical benefits. However, HER2 overexpression and gene amplification have also been reported in other cancers like gastric cancer, non...
שמור ב:
| Principais autores: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2023-05-01
|
| סדרה: | Frontiers in Molecular Biosciences |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fmolb.2023.1165781/full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|